Literature DB >> 27035516

Optimal sequence of antisense DNA to silence YB-1 in lung cancer by use of a novel polysaccharide drug delivery system.

Hiroto Izumi1, Shohei Nagao2, Shinichi Mochizuki2, Nobuaki Fujiwara2, Kazuo Sakurai2, Yasuo Morimoto1.   

Abstract

Silencing Y-box binding protein 1 (YB-1) can be an excellent target for cancer therapy and many lung cancer cells express the polysaccharide-recognition receptor Dectin-1. We designed a Dectin-1 targeting vehicle delivering YB-1-antisense DNA. First, we selected five optimal antisense DNA sequences to silence YB-1 from among 153 candidates. We chose the sequence closest to the start codon (AS014), and attached dA40 to the 3' end; dA40 promotes complex formation with a β-(1➝3)-d-glucan called schizophyllan (SPG). The resultant complexes were applied to 12 human-oriented lung cancer cell lines, and cell viability was examined. The cell lines exhibited decreased viability and showed strong affinity to bind SPG, suggesting the AS014/SPG complex entered the cells via the Dectin-1 mediated pathway.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27035516     DOI: 10.3892/ijo.2016.3451

Source DB:  PubMed          Journal:  Int J Oncol        ISSN: 1019-6439            Impact factor:   5.650


  2 in total

Review 1.  Oncogenic Y-box binding protein-1 as an effective therapeutic target in drug-resistant cancer.

Authors:  Michihiko Kuwano; Tomohiro Shibata; Kosuke Watari; Mayumi Ono
Journal:  Cancer Sci       Date:  2019-04-07       Impact factor: 6.716

2.  YBX1 Enhances Metastasis and Stemness by Transcriptionally Regulating MUC1 in Lung Adenocarcinoma.

Authors:  Qiang Xie; Shilei Zhao; Wenzhi Liu; Yanwei Cui; Fengzhou Li; Zhuoshi Li; Tao Guo; Wendan Yu; Wei Guo; Wuguo Deng; Chundong Gu
Journal:  Front Oncol       Date:  2021-12-15       Impact factor: 6.244

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.